Introduction
Proteins are the workhorses of living systems, catalysing reactions essential for metabolism, detecting and responding to environmental stimuli, providing structural integrity to the cell structure and detecting pathogens among numerous other functions. Many of these functions are of academic or industrial interest, necessitating the purification of the relevant proteins. Typically, this is accomplished by expressing a recombinant version of the protein of interest fused to an affinity tag that enables column purification using an appropriate affinity matrix. Whilst this process enables routine purification of large amounts of target protein, the presence of the affinity tag fused to the protein can interfere with downstream applications or function [1, 2] . The tag may be removed by cleavage of a protease site placed between the target protein and the affinity tag, followed by a step to separate the protein and affinity tag. Nonetheless, most sequence-specific proteases have amino acid requirements at both the N-and C-terminal sides of the cleavage site [3] , leaving a small "stub" still attached to the protein of interest. This may be unfavourable for certain downstream applications and in the case of therapeutic proteins, it may raise the possibility of an immune response.
Serial chromatography purifications of cellular lysates can be used to isolate proteins of interest based on their size, charge and pI. However this method is often laborious, non-generic and does not guarantee fully pure protein. Researchers have previously developed methods to fully remove any trace of the affinity tag. A system comprising a column-immobilized mutant subtilisin which is inactive in the absence of fluoride ions, and a target protein fused to subtilisin prodomain at its N terminus has been developed [4] . The prodomain-target protein fusion is loaded onto the mutant subtilisin column, non-specific proteins washed off and cleavage at the junction of the prodomain-protein of interest triggered by the addition of fluoride ions at high concentration. This method requires a specialised column and results in the presence of fluoride ions in the eluate which may have to be removed prior to downstream applications.
Another system developed involves the fusion of the protein of interest to a mutant intein and chitin binding domain at the C terminus [5] . The expressed protein is bound to a chitin matrix and the cellular proteins and debris are washed out. Addition of a strong reducing agent triggers the intein, thereby severing the link between the intein and the native target protein, which is eluted. This process also requires a specialised column and results in the presence of a strong reducing agent in the elution buffer.
The TAGzyme method from Qiagen uses aminopeptidases to cleave off N terminal histidine tags, while preventing the cleavage of target protein residues by using "stop points" such as glutamine. These "stop point" containing proteins are processed by Qcyclase which converts the N terminal glutamine into pyroglutamate. This can then be cleaved by an aminopeptidase (pGAPase) to yield native protein. However, the necessity for inserting genetically coded "stop points" for most proteins, and a multi-step process necessary for obtaining native protein leaves substantial room for improvement.
We have therefore developed a purification system to generate native (i.e. completely untagged) proteins of interest (Fig. 1) . This requires expression of a fusion protein comprising the ePDZ-b affinity clamp domain adjacent to a sub-optimal sequence-specific protease cleavage site (preferred residues at P1' and P2' are removed) followed immediately by the protein of interest. The cognate protease is expressed with a C-terminal tag comprising the ARVCF peptide sequence that binds ePDZ-b very tightly (K d < 5 nM) [6] . Typically, the presence of methionine at the P1' position in addition to steric hindrance posed by the folded target protein would render cleavage at this site sub-optimal due to compromised protease affinity. However, fusion to the interacting proteinpeptide pair enforces proximity, allowing a much faster reaction rate by increasing the effective concentration of protease in the vicinity of a sub-optimal cleavage site. The concept of enforced proximity has previously been described to generate proteins with native amino termini from MBP fusion proteins, although these still retained C-terminal histidine tags [7] .
Here, we show that this method leads to increased amounts of native protein and is readily transposable onto pre-existing protocols and reagents used for purification of proteins labelled with the ubiquitous histidine tag.
Materials and methods
Unless otherwise specified, all oligonucleotides used in this work were from Integrated DNA Technologies (Singapore), chemical reagents from Sigma and SplB protease from Thermo Scientific. His-tag purification columns were purchased from GE Healthcare.
Endogenous TEV protease comprising N-terminal histidine tag and the MPB-ENLYFQS-PH-G1VCA protein were gifts from the Robinson laboratory.
Plasmid construction
Expression cassettes were made by PCR amplification of individual genes with oligonucleotides incorporating linker extensions which could then be joined to other genes via Splicing by Overlap Extension (SOE). Fusion genes were inserted into expression vector pET22 (Kan) (pET22b with ampicillin resistance cassette replaced with kanamycin resistance) by infusion cloning. Oligonucleotide sequences are listed in Supporting Information (Table S1 ).
Protease gene constructs
SplB proteases were expressed with a protein A domain fused at the N terminus, an SplB cleavage site "WELQ" immediately preceding the first amino acid of the mature SplB protease, and a 6X histidine tag followed by the ARVCF peptide at the C terminus (protein A-GGWELQ-mature SplB-His tag-ARVCF peptide). The protein A is removed by cleavage at the "WELQ" site for a small minority of fusion proteins during protein expression, forming active SplB protease, which in turn cleaves more of the fusion protein, resulting in a rapid chain reaction yielding mature SplB-His tag-ARVCF peptide.
The Protein A open reading frame (ORF) was amplified using oligonucleotides oSN684 and oSN1096. oSN1096 appends a sequence coded as "GGSGKGGWEL" at the 3' of protein A. SplB was PCR-amplified with oSN1099 and oSN875. oSN875 appends a partial His tag to the 3' of SplB. oSN1099 appends a sequence complementary to that of oSN1096, enabling SOE PCR of these two amplicons to yield protein A-WELQ-SplB-partial His tag cassette.
Simultaneously, the pET22b (kan) vector was amplified by inverse PCR using oSN1183 and oSN1184, which have complementary 5' ends for infusion cloning, followed by intra-plasmid infusion cloning (Clontech), creating a vector which has the "PQPVDSWV" coding ARVCF peptide just downstream of the XhoI site. This vector was then linearized with NdeI/XhoI, and the fusion ORF protein A-WELQ-SplB-partial His tag was inserted by infusion cloning yielding protein A-WELQ-SplB-His tag-ARVCF peptide in pET22b (Kan) vector.
The TEV-AP4 protein expression construct encoded the ORF for a maltose binding protein (MBP)-optimal TEV cleavage site (ENLYFQS)-TEV-GGGHHHHHHGGDSWV fusion protein. The ORF was synthesized (Genscript) and inserted into the NdeI/XhoI sites in pET22b vector. Note the TEV expressed incorporated the S219V mutation to reduce autolysis [8] . The TEV protease auto-cleaves itself from MBP after expression and is purified using the 6-histidine tag preceding the truncated ARVCF peptide (DSWV, indicated in bold above). The vector pRK793 [8] was used to express histidine-tagged TEV comprising the S219V mutation.
SplB-His tag-truncated ARVCF peptide constructs
These were constructed by doing inverse PCR with the abovementioned protein A-WELQ-SplB-His tag-ARVCF construct using the oligonucleotides oSN1225, 1226, 1227, 1228 and 1230 with the common reverse oligonucleotide oSN1229 to yield constructs expressing ARVCF peptides PQPVDSWV, QPVDSWV, PVDWSV, VDSWV and DSWV respectively.
SplB-truncated His tag-DSWV constructs
The protein A-WELQ-SplB-truncated His tag-DSWV was created by inverse PCR of the protein A-WELQ-SplB-6x His tag-DSWV construct described above with oSN1396 and oSN1397 followed by intra-plasmid infusion to truncate the number of histidines from 6 to 5.
For the construct with 4 histidines, the original protein A-WELQ-SplB-6x His tag-DSWV ORF was amplified with oSN684 and oSN1407, followed by infusion into a vector obtained by inverse PCR using the oligonucleotides oSN1229 and oSN359.
ePDZ-b -WELQ-protein constructs
The ePDZ-b ORF was PCR-amplified using tandem oligonucleotides oSN1344 and 1348 and reverse oligonucleotide oSN1386 to attach a 6x histidine tag to the N terminus of ePDZ-b and a linker coding for amino acids "WELQM" to the 3' terminus. The ORF for LSSmOrange (OFP) was PCR-amplified using oSN1318 and oSN1312, followed by SOE PCR to create histidine tag-ePDZ-b-WELQ-OFP expression cassette. This was then inserted by infusion cloning into pET22b (Kan) vector obtained by inverse PCR using oSN359-1384.
ePDZ-b -TEV site-protein constructs
The previously constructed ePDZ-b-WELQ-OFP plasmid was inverse PCR-amplified with oSN1410 and oSN1315. The OFP ORF (PCR-amplified using oSN1414-1412) was inserted into this plasmid by infusion cloning to yield His tag-ePDZ-b-ENLYFQ-OFP. This plasmid was subsequently PCR-amplified using primers oSN1415 and oSN1416 and the fibronectin 10Fn3 domain ORF (obtained by amplifying plasmid 10FN3-HA_pET22b with primers oSN 1417 and 1418) inserted via infusion cloning. The resulting His tag-ePDZ-b-ENLYFQ-10Fn3 expression plasmid was subsequently amplified by inverse PCR using primer pairs oSN1419/1420 and oSN1419/1421 and products intramolecularly ligated post-phosphorylation to yield constructs expressing His-tag-ePDZ-b-ENLYFQ-MGGS-10Fn3 and His-tag-ePDZ-b-ENLYFQ-MGGSGGS-10Fn3 respectively.
Protein expression
All protein expression was carried out in E. coli BL21 (DE3) using IPTG induction of the T7 promoter. Colonies were inoculated overnight (ON) in 10 mL TY medium supplemented with the appropriate antibiotic at 37 C with shaking at 180 rpm. The next day, the cultures were diluted into 800 mL of fresh medium and allowed to grow at 37 C to an OD600 of 0.5, upon which IPTG (1 mM final) was added. Induction was allowed to proceed overnight at room temperature. The next day, cells were pelleted down and stored at À20 C until further processing.
Protein purification
Cell pellets obtained as described above were resuspended in 20 mL of PBS-Tween or other buffers as mentioned in the text followed by lysis by sonication. The lysate was centrifuged at 14800 rpm for 10 min in 50 mL Falcon tubes and the supernatant was collected. In parallel, a 1 mL FF His-trap column (GE Healthcare) was washed with 10 mL of the same buffer in which the pellet was resuspended. After collecting the cell lysate supernatant, it was run through the column, followed by washing with 10 mL of washing buffer (the same buffer used for cell pellet resuspension). Thereafter elution buffer (50 mM Sodium Phosphate þ 300 mM NaCl þ 500 mM Imidazole) was run through the column and 1 mL fractions were collected. All other fractions were also collected and the normalized volumes of the fractions were run on an SDS-PAGE gel followed by staining by Instant Blue for visualization.
The fractions containing high concentrations of pure protein were mixed with glycerol to a final volume of 50% glycerol and stored at À20 C.
Go Native protein purification
Cell pellets were resuspended and lysed as described above. The cell lysate was loaded on an equilibrated His-trap column followed by washing with 10 mL of buffer. Next, 5 mL of the relevant protease (0.5 mg/mL) was loaded on the column. The column was capped and incubated at room temperature for the relevant duration. Thereafter, washing buffer was run through the column and fractions collected. Finally, imidazole elution buffer was run through the column. All fractions were collected and normalized volumes electrophoresed on an SDS-PAGE gel followed by staining with Instant Blue.
Mass spectrometry/N-terminal protein sequencing
To elucidate cleavage sequence specificity mass spectrometry analysis was performed. Following SDS-PAGE separation and Coomassie visualisation, gel band with protease cleaved product was excised and subjected to "in-gel" digestion [9] . Following desalting, sample was injected and separated using Orbitrap Fusion mass spectrometer coupled to nanoUHPLC system Easy LC1000 (Thermo) in a 45 min gradient. To generate peak list Proteome Discoverer 1.4 software was used. Searches were done using Sequest HT algorithm against Human Uniprot database appended with specific target sequence (87458 entries) with following parameters: precursor mass tolerance (MS) 10 ppm, (MS/MS) IT-MS/MS 0.6 Da; noenzyme; 2 miss cleavages; Static modifications: Carboamidomethyl (C), Variable modifications: Oxidation (M), Deamidated (NQ). N-terminal sequencing of gel-purified protein [10] was carried out by Biosynthesis (USA).
Results
We first tested the principle using ePDZ-b fused to the target protein (orange fluorescent protein, OFP) and ARVCF peptide fused to SplB protease (SplB-AP). SplB protease cleaves after the sequence WELQ with methionine at the P1' position poorly tolerated [11, 12] . When combined with potential steric exclusion by the protein of interest being purified, methionine at P1' will pose barriers to optimal SplB protease cleavage. The WELQ peptide sequence was introduced between ePDZ-b and OFP. Incubation of the fusion substrate (ePDZ-b-WELQ-OFP) with a stoichiometric excess of either SplB-AP or commercially available SplB protease (SplB-COM) resulted in cleavage and generation of native OFP (Fig. 2) . However, this was notably more efficient for SplB-AP compared to SplB-COM and SplB fused to a control peptide that does not interact with ePDZ-b (SplB-CON) (compare lanes 2,6e8). Neither SplB-COM or Spl-CON was able to completely digest the fusion substrate. The increased efficiency of SplB-AP was more pronounced when it was reduced to sub-stoichiometric levels compared to substrate (Fig. 2,  compare lanes 9, 13e15 and lanes 16, 20e22) . The very high affinity between ePDZ-b and ARFCP peptide may result in prolonged tethering of protease to ePDZ-b after cleavage of target protein. This would reduce "turn-over" of the protease, necessitating use of higher stoichiometric amounts. We tested this hypothesis by reducing the affinity of the ePDZ-b-ARVCF peptide interaction by serially truncating the ARVCF peptide fused to SplB from 8 to 4 amino acids (PQPVDSWV to DSWV). At high protease concentration, no variation was observed in cleavage efficiency (Fig. 2, lanes  2e5) . At sub-stoichiometric amounts, 3 and 4 amino acid truncations of the ARVCF peptide showed clear improvements in activity compared to full-length peptide (Fig. 2, compare lane 16 with  18e19) . Furthermore, the overall activity compared to the SplB-CON and SplB-COM was significantly enhanced (compare lanes 18e19 and 20e21).
We next applied the principle to TEV protease, one of the most ubiquitous enzymes used to remove affinity tags that optimally cleaves the consensus sequence ENLYFQYS [13, 14] . We constructed a fusion substrate wherein this sequence was truncated to ENLYFQ, and placed between the ePDZ-b and OFP components. TEV is able to cleave when serine at P1' position is replaced by methionine with marginal loss of activity [15] . However, steric constraints due to the tightly folded N-terminal region of OFP could impact negatively on cleavage. The results show clearly improved cleavage when TEV is fused to the optimised 4-amino acid truncated ARVCF peptide (TEV-AP4) (Fig. 3A) . Notable cleavage was observed after only 30 min incubation with majority of substrate beng cleaved after 2.5 h. In comparison, TEV protease only showed significant cleavage after 24 h incubation. Note that both the TEV-AP4 and TEV proteins used comprise the S219A mutation introduced to reduce autolysis [8] . A control experiment using a fusion substrate comprising the full TEV consensus sequence (ENLYFQS) led to equivalent cleavage by both wild-type TEV and TEV-AP4 (Fig. 3B) . The endogenous TEV protease (minus the S219V mutation) showed even poorer cleavage when compared to TEV-AP4 for the same substrate (Fig. S1 ). We next assayed TEV-AP4 on a fusion substrate where OFP was replaced with the fibronectin 10Fn3 domain (ePDZ-b-ENLYFQY10Fn3). As before, significantly enhanced cleavage was obtained in very short times when using TEV-AP4 compared to TEV (Fig. 4A) . Given the highly compact 10Fn3 fold [16] , it is likely that steric constraints inhibit cleavage by TEV. Introduction of GGS or GGSGGS linkers (to yield ePDZ-b-ENLYFQYMGGS-10Fn3 and ePDZ-b-ENLYFQYMGGSGGS-10Fn3 respectively) resulted in improved cleavage by TEV, yet this was still considerably less than for TEV-AP4 (Fig. 4B,C) . As before, endogenous TEV also performed poorly using this substrate set (Fig. S2) .
We next explored whether the enforced-proximity concept was applicable to conventional on-column cleavage and purification protocols using histidine tagged proteins. Complete immobilisation of protease via its histidine tag could reduce turnover during oncolumn cleavage of a co-immobilised substrate, necessitating use of increased amounts for efficient cleavage. Addition of 30 mM imidazole alleviated this constraint, resulting in improved cleavage efficiencies using histidine tagged ePDZ-b -WELQ-OFP and SplB-AP proteins (Fig. S3) . These conditions were used for the on-column full-length ARVC-pep tag at C-terminus (SplB-PQPVDSWV) and 3 progressively shortened peptide tags. These tagged proteases all showed improved cleavage to yield native OFP (red arrow) compared to SplB protease tagged with a non-specific C-terminal peptide (SplB-CON) and commercial non-tagged SplB protease (SplB-COM). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 3 . Improved cleavage of target fusion protein comprising TEV cleavage site with methionine at P1' position. A) The ePDZ-b-ENLYFQ-OFP fusion protein (ENLYFQ is truncated consensus TEV recognition sequence) was incubated with either TEV protease tagged with optimised 4 amino acid ARVC-peptide (TEV-AP4) (lanes 2e9) or untagged TEV protease (lanes 14e21) for indicated times. Native OFP (arrowed red) was rapidly generated through use of TEV-AP4 compared to TEV. Lanes 11 and 23 show untreated fusion substrate. Lanes 12 and 24 show TEV-AP4 and TEV proteases respectively (dotted arrows). Note both comprise the S219V autolysis resistance mutation. B) Same as in A, except using the fusion protein substrate MPB-ENLYFQS-PH-G1VCA with optimal TEV recognition sequence (underlined). Similar cleavage was observed for both TEV-AP4 (lanes 2e9) and TEV (lanes 14e21) to yield S-PH-G1VCA. Lanes 12 and 24 respectively show TEV-AP4 and TEV proteases (dotted arrows). Lanes 11 and 23 show untreated fusion substrate. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) cleavage of histidine tagged ePDZ-b -ENLYFQ-OFP protein by histidine tagged TEV-AP4. Upon elution with PBS, the yield of native OFP was significantly increased when histidine tagged TEV-AP4 was used compared to histidine tagged endogenous TEV (Fig. 5A , compare lanes 6 and 15). Both mass spectrophotometry and Nterminal sequencing analysis confirmed correct cleavage by TEV-AP4 to yield OFP with an N-terminal methionine (Figs. S4 and S5). We also carried out on-column cleavage of the histidine tagged ePDZ-b-ENLYFQYMGGS-10Fn3 substrate, this time comparing with histidine-tagged TEV(S219V). As before, TEV-AP4 showed improved cleavage on-column (Fig. 5B ).
Discussion
Examples are abound in nature of proteins that have evolved to serve as platforms to bring reactants into close proximity [17] . This mechanism improves the affinity (i.e. Km) component of catalysis, which can often be rate limiting. An example is the Ste5 platform in budding yeast, which serves as a platform to co-localize various reactants, enabling faster signalling [18] . Another example is the Cdc2 kinase which is directed to its targets by cyclins [19] . Similarly, enzymes such as polymerases involved in the formation of covalent bonds between two or more molecules need to have the ability to bind the reactants and bring them into close proximity before catalysis [20] . This principle has previously been described to enhance the efficiency of N-degron activation by TEV and to select for TEV variants with increased P1' substrate tolerance in vivo [21, 22] . Here, the interacting SF3b155 381À424 protein domain and human spliceosome subunit p14 were respectively tethered to the N-degron and protease. We have extended this concept using ePDZ-b and a minimised ARVCF peptide pair to enhance protease cleavage for in vitro removal of affinity tags. ePDZ-b comprises a synthetic bi-domain protein "affinity clamp" evolved for high affinity binding to the ARVCF peptide [6] . Results using SplB protease indicated that enforced proximity can overcome issues of steric hindrance arising from the presence of a bulky hydrophobic amino acid at P1' and/or where the structured N-terminus of a protein can limit access of protease to an adjacent cleavage site. Whilst TEV has been shown to tolerate a range of amino acids at the P1' position, we have shown greatly improved activity when methionine is present at this position by promoting co-localisation. This result also indicates that the ePDZ-b component of the substrate fusion protein is not contributing to steric hindrance, as reported for other fusion partners [23] . TEV activity is~10-fold reduced at 4 C (commonly used for prolonged on-column digestion) compared to its activity at 30 C [24] . Our data shows that cleavage to yield native proteins is rapidly expedited by enforced co-localisation at room temperature (~22 C). This opens up the option of incubation at temperatures closer to the TEV optimum for shorter periods that preserve integrity of target proteins.
In sum, we have described facile use of the ePDZ-b/ARVCF peptide pair to optimize sub-optimal cleavage by site-specific proteases and generate completely tag-free target proteins. We are currently evaluating the "Go Native" concept in the context of other commonly used proteases and affinity tags to further determine its broad applicability.
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